|
nasdaq:edit
|
4995975
|
Apr 21st, 2024 12:00AM
|
Editas Medicine
|
42K
|
305.00
|
Open
|
|
Apr 20th, 2024 11:22PM
|
Apr 20th, 2024 11:22PM
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
|
Open
|
Genome Editing, In Vivo (in body) Editing, Engineered Cell Medicines, Ocular Medicines, Genetic Diseases, Blood Diseases, Sickle Cell Disease, Cancer, Rare Diseases, Immunogenetics, Transfusion-Dependent Beta Thalassemia, and Hematopoietic Stem Cells
|
Open
|
11 Hurley St
|
Cambridge
|
Massachusetts
|
US
|
02141
|
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
4995975
|
Apr 20th, 2024 12:00AM
|
Editas Medicine
|
42K
|
305.00
|
Open
|
|
Apr 19th, 2024 11:20PM
|
Apr 20th, 2024 04:55PM
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
|
Open
|
Genome Editing, In Vivo (in body) Editing, Engineered Cell Medicines, Ocular Medicines, Genetic Diseases, Blood Diseases, Sickle Cell Disease, Cancer, Rare Diseases, Immunogenetics, Transfusion-Dependent Beta Thalassemia, and Hematopoietic Stem Cells
|
Open
|
11 Hurley St
|
Cambridge
|
Massachusetts
|
US
|
02141
|
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
4995975
|
Apr 19th, 2024 12:00AM
|
Editas Medicine
|
42K
|
304.00
|
Open
|
|
Apr 18th, 2024 11:27PM
|
Apr 18th, 2024 11:27PM
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
|
Open
|
Genome Editing, In Vivo (in body) Editing, Engineered Cell Medicines, Ocular Medicines, Genetic Diseases, Blood Diseases, Sickle Cell Disease, Cancer, Rare Diseases, Immunogenetics, Transfusion-Dependent Beta Thalassemia, and Hematopoietic Stem Cells
|
Open
|
11 Hurley St
|
Cambridge
|
Massachusetts
|
US
|
02141
|
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
4995975
|
Apr 18th, 2024 12:00AM
|
Editas Medicine
|
42K
|
304.00
|
Open
|
|
Apr 17th, 2024 11:35PM
|
Apr 18th, 2024 06:15PM
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
|
Open
|
Genome Editing, In Vivo (in body) Editing, Engineered Cell Medicines, Ocular Medicines, Genetic Diseases, Blood Diseases, Sickle Cell Disease, Cancer, Rare Diseases, Immunogenetics, Transfusion-Dependent Beta Thalassemia, and Hematopoietic Stem Cells
|
Open
|
11 Hurley St
|
Cambridge
|
Massachusetts
|
US
|
02141
|
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
4995975
|
Apr 17th, 2024 12:00AM
|
Editas Medicine
|
42K
|
304.00
|
Open
|
|
Apr 16th, 2024 11:17PM
|
Apr 17th, 2024 02:40PM
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
|
Open
|
Genome Editing, In Vivo (in body) Editing, Engineered Cell Medicines, Ocular Medicines, Genetic Diseases, Blood Diseases, Sickle Cell Disease, Cancer, Rare Diseases, Immunogenetics, Transfusion-Dependent Beta Thalassemia, and Hematopoietic Stem Cells
|
Open
|
11 Hurley St
|
Cambridge
|
Massachusetts
|
US
|
02141
|
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
4995975
|
Apr 16th, 2024 12:00AM
|
Editas Medicine
|
42K
|
303.00
|
Open
|
|
Apr 15th, 2024 11:13PM
|
Apr 16th, 2024 10:56AM
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
|
Open
|
Genome Editing, In Vivo (in body) Editing, Engineered Cell Medicines, Ocular Medicines, Genetic Diseases, Blood Diseases, Sickle Cell Disease, Cancer, Rare Diseases, Immunogenetics, Transfusion-Dependent Beta Thalassemia, and Hematopoietic Stem Cells
|
Open
|
11 Hurley St
|
Cambridge
|
Massachusetts
|
US
|
02141
|
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
4995975
|
Apr 15th, 2024 12:00AM
|
Editas Medicine
|
41K
|
303.00
|
Open
|
|
Apr 14th, 2024 11:08PM
|
Apr 15th, 2024 04:37PM
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
|
Open
|
Genome Editing, In Vivo (in body) Editing, Engineered Cell Medicines, Ocular Medicines, Genetic Diseases, Blood Diseases, Sickle Cell Disease, Cancer, Rare Diseases, Immunogenetics, Transfusion-Dependent Beta Thalassemia, and Hematopoietic Stem Cells
|
Open
|
11 Hurley St
|
Cambridge
|
Massachusetts
|
US
|
02141
|
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
4995975
|
Apr 14th, 2024 12:00AM
|
Editas Medicine
|
41K
|
303.00
|
Open
|
|
Apr 13th, 2024 10:57PM
|
Apr 13th, 2024 10:57PM
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
|
Open
|
Genome Editing, In Vivo (in body) Editing, Engineered Cell Medicines, Ocular Medicines, Genetic Diseases, Blood Diseases, Sickle Cell Disease, Cancer, Rare Diseases, Immunogenetics, Transfusion-Dependent Beta Thalassemia, and Hematopoietic Stem Cells
|
Open
|
11 Hurley St
|
Cambridge
|
Massachusetts
|
US
|
02141
|
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
4995975
|
Apr 13th, 2024 12:00AM
|
Editas Medicine
|
41K
|
303.00
|
Open
|
|
Apr 12th, 2024 10:49PM
|
Apr 13th, 2024 11:23AM
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
|
Open
|
Genome Editing, In Vivo (in body) Editing, Engineered Cell Medicines, Ocular Medicines, Genetic Diseases, Blood Diseases, Sickle Cell Disease, Cancer, Rare Diseases, Immunogenetics, Transfusion-Dependent Beta Thalassemia, and Hematopoietic Stem Cells
|
Open
|
11 Hurley St
|
Cambridge
|
Massachusetts
|
US
|
02141
|
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
4995975
|
Apr 12th, 2024 12:00AM
|
Editas Medicine
|
41K
|
303.00
|
Open
|
|
Apr 11th, 2024 10:53PM
|
Apr 12th, 2024 08:18AM
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
|
Open
|
Genome Editing, In Vivo (in body) Editing, Engineered Cell Medicines, Ocular Medicines, Genetic Diseases, Blood Diseases, Sickle Cell Disease, Cancer, Rare Diseases, Immunogenetics, Transfusion-Dependent Beta Thalassemia, and Hematopoietic Stem Cells
|
Open
|
11 Hurley St
|
Cambridge
|
Massachusetts
|
US
|
02141
|
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|